Eli Lilly's Alzheimer's drug slows cognitive decline: Study

Eli Lilly's Alzheimer's drug showed a 36 percent reduction in the disease's progression in patients after 18 months and a 60 percent reduction in cognitive decline in less severe patients. Yahoo Finance Health Care Reporter Anjalee Khemlani discusses the latest study on the experimental drug, as well as Pfizer's partnership with Flagship Pioneering.